Amit Bar-Or, MD, FRCPC / Bruce Cree, MD, PhD, MAS - Realizing the Full Clinical Potential of Sphingosine-1-Phosphate Receptor Modulation to Improve Outcomes in Patients With Multiple Sclerosi
Go online to PeerView.com/VTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple sclerosis (MS) is a debilitating, chronic inflammatory disease that is characterized by demyelination and neurodegeneration of the central nervous system. Efforts to provide effective treatments for individuals with MS have led to FDA approval of many disease-modifying therapies since 2010, including the sphingosine-1-phosphate receptor (S1PR) modulators. Newer-generation S1PR modulators have been developed to preferentially target receptors 1 and 5, with the goal of improving safety profiles, which is expected to make these agents better treatment options for more MS patients. Moreover, the S1PR modulators have demonstrated a range of therapeutic benefits, including effects on gray matter atrophy. In this activity, based on a recent live webcast, our expert faculty offer insights into the role of S1PRs in the pathophysiology of MS and therapeutic benefits of S1PR modulators, including effects on brain atrophy metrics, in patients with MS. Upon completion of this activity, participants will be able to: Review the proposed mechanisms of action for sphingosine-1-phosphate receptor (S1PR) modulators and how they may address the pathophysiological defects associated with multiple sclerosis, Summarize key efficacy, safety, and tolerability data available for established, novel, and investigational S1PR modulators for the treatment of multiple sclerosis, Describe the therapeutic potential of current and emerging S1PR modulators for patients with multiple sclerosis, including impact on whole brain and gray matter atrophy metrics, Apply available evidence on established and novel S1PR modulators when managing patients with multiple sclerosis.